Noctrix Health, Inc.
8
0
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
60%
3 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS
Role: lead
Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation
Role: lead
Response to an Investigational Device in Patients With Restless Legs Syndrome
Role: lead
Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)
Role: lead
Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS
Role: lead
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction
Role: lead
Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS
Role: lead
Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome
Role: lead
All 8 trials loaded